ARK Invest bought 1.25M shares of Recursion Pharmaceuticals for $4.33M ARK added 37,075 CRISPR Therapeutics shares worth $1.97M PagerDuty was the biggest sell at $3.89M for 566,650 shares ARK also cut ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

DNA Vibe appointed Maria Del Rio as its chief marketing officer. Magnet Biomedicine appointed Bharat Reddy as chief business officer. Target RWE named Sriram Krishnan, PhD as chief product officer.

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

This project implements a solution for the Travelling Salesman Problem (TSP) using bitmasking and dynamic programming. It calculates the shortest possible route that visits every city exactly once and ...

This study develops a unified framework for optimal portfolio selection in jump–uncertain stochastic markets, contributing both theoretical foundations and computational insights. We establish the ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...